Physician profile
Sule Salami
NPI 1700027299
$6,208.32
in general payments reported to CMS, 2019-2025
29 companies · $2,417 in 2025
The $2,417 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $443 · 2021: $210 · 2022: $586 · 2023: $910 · 2024: $1,014 · 2025: $2,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258 · Travel and Lodging: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.88 |
| Travel and Lodging | $1,082.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,681.30 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $635.36 | 2021-2025 | Resolute Onyx, Hawkone, Reveal Linq |
| Abiomed | $483.38 | 2019-2024 | Impella |
| Boston Scientific Corporation | $391.24 | 2019-2025 | Watchman Flx, Resonate El Icd Vr, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $345.16 | 2019-2024 | Xarelto |
| Amgen INC. | $288.03 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $275.39 | 2020-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $246.34 | 2021-2025 | |
| Medtronic Vascular, INC. | $221.44 | 2019-2020 | |
| Pfizer INC. | $215.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $203.20 | 2021-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.23 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $152.96 | 2021-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $142.98 | 2022-2023 | Optimizer |
| Shockwave Medical, INC | $142.09 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $123.46 | 2019-2024 | Jot Dx |
| Lundbeck LLC | $121.12 | 2019-2020 | |
| Philips North America LLC | $55.56 | 2020-2022 | |
| Altathera Pharmaceuticals LLC | $51.45 | 2023 | Sotalol Hydrochloride |
| Bard Peripheral Vascular, INC. | $43.87 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.49 | 2025 | |
| Sanofi-Aventis U.S. LLC | $32.83 | 2019 | |
| Resmed Corp | $19.94 | 2024 | |
| Kestra Medical Technology Services, INC. | $19.49 | 2025 | Assure Wcd |
| Glaxosmithkline, LLC. | $18.67 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $18.59 | 2022 | |
| Astellas Pharma US INC | $17.66 | 2019 | |
| Terumo Medical Corporation | $15.98 | 2022 | |
| Cardiovascular Systems INC. | $15.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sule Salami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.